GLP-1类似物联合二甲双胍治疗2型糖尿病患者的临床疗效及预后  

Clinical efficacy and prognosis of glucagon-like peptide-1 combined with metformin in the treatment of patients with type 2 diabetes

作　　者：赵菁[1] 薛玉喜[1] 

机构地区：[1]南京医科大学附属无锡市人民医院特需医疗科,江苏无锡214000

出　　处：《实用临床医药杂志》2017年第7期43-46,共4页Journal of Clinical Medicine in Practice

摘　　要：目的探讨GLP-1类似物联合二甲双胍在2型糖尿病患者中的临床疗效及预后。方法选取70例2型糖尿病患者,随机分为观察组和对照组。对照组采用二甲双胍联合西格列汀治疗,观察组采用利拉鲁肽联合二甲双胍进行治疗。比较2组患者的糖化血红蛋白(HbA_(1c))、空腹血糖(FBG)、餐后2 h血糖(2 hPBG)、胰岛素抵抗指数(HOMA-IR)、体质量指数(BMI)等指标和血脂水平,分析2组不良反应发生情况。结果观察组治疗后HbA_(1c)、FBG、2 hPBG、HOMA-IR、BMI水平均显著低于对照组(P<0.05),治疗后观察组血脂水平显著优于对照组(P<0.05)。2组患者不良反应发生率均较低。结论 GLP-1类似物联合二甲双胍治疗糖尿病的临床疗效良好。Objective To explore the clinical efficacy and prognosis of glucagon-like pep- tide-1 combined with metformin in the treatment of patients with type 2 diabetes. Methods A total of 70 patients with type 2 diabetes were selected and randomly divided into observation group and con- trol group. The observation group was treated with metformin combined with｜iraglutide, and the con- trol group was treated with metformin combined with sitagliptin. Theglycosylated hemoglobin （HbAIo）, fasting blood glucose （FBG）, two hours postprandial blood glucose （2hPBG）, homeosta- sis model assessment-insulin resistance index （HOMA-IR）, body mass index （BMI） and blood lipid levels were compared between the two groups. Incidence of complications was analyzed. Results Af- ter treatment, the HbA1c, FBG, 2 hPBG, HOMA-IR, BMI and blood lipid levels in observation group were significantly better than those in control group （P 〈 0.05）. The incidence rate of adverse reactions was low in both groups. Conclusion glucagon-like peptide-1 combined with metformin is effective in the treatment of patients with type 2 diabetes.

关 键 词：利拉鲁肽 二甲双胍 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]